|
 |
|
|
To
view a summary of Current Treatments for Psoriasis, click
here.
Summary
of Key ABCream Features
|
OVERVIEW
ABCream
is an effective topical formulation of monoclonal
antibodies consisting of anti-IL-8 neutralizing antibody that
specifically inhibit a key molecule, interleukin-8 (IL-8),
which plays pivotal pathological roles in psoriasis when
over-expressed in skin.
IL-8
levels can be elevated 150-fold in psoriatic tissue when
compared to normal tissue. Likely effects of IL-8 in causing
or promoting tissue damage are a result of IL-8 being a strong
chemotaxis factor for neutrophils, a strong growth factor of
epidermal cells, and a potent angiogenesis factor.
EFFECTIVENESS
ABCream
contains anti-human IL-8 antibodies that neutralize excessive
IL-8,
which can modulate abnormal proliferation and differentiation
of keratinocytes and eliminate the gathering of neutrophils,
therefore producing an anti-inflammatory response in the
psoriatic skin.
ABCream
can block the abnormal blood supply by reducing the
angiogenesis factor, IL-8, resulting in the reduction of over
proliferating cells.
SAFETY
Murine
antibodies used in topical application are able to generate
satisfactory therapeutic effect without causing HAMA response
(Human Anti-Mouse Antibody), and are therefore safe and
appropriate to use in the topical treatment of psoriasis.
Humanized antibody can result in a final antibody product that
is different in structure from the original mouse antibody,
leading to a decrease in specificity or a loss in affinity.
Topical
applications do not generally affect the levels and expression
of immunological cytokines in the body. Hypersensitive
reaction and related symptoms are that are often observed in
association with systemic injection of exogenous proteins are
avoided.
RESULTS
Anti-IL-8
antibodies are capable of penetrating through skin into
psoriatic lesions in sufficient amounts to show therapeutic
effects. Our long-term study has shown that the changes
of antibody titer are gradual, indicating that the cream
substance has a protective effect on antibody, and the
antibody stability is maintained in the cream formulation for
at least one year.
ABCream
may be effective in treatment of other inflammatory skin
conditions as well. Preliminary observations suggest that it
may also be used for treatment of eczema, a common skin
condition.
Results
of Phase III clinical trials in People's
Republic
of China (Phase IV trials complete as well)
49%
to 53.8% of patients achieved a greater than 60%
improvement and 12.9% to 15.3% of patients achieved a greater
than 90% improvement in PASI scores after a six week treatment
cycle with ABCream.
To
view the Patent Status of ABCream,
click
here.
|
